Table 8.

The baseline data and the renal outcome of two subgroups in 121 patients who were regularly followed and treated with RAS blockade together with immunosuppressive therapy after 3 months of RAS blockade therapy alone

Response Patients (n = 58)Non-Response Patients (n = 63)P
At time of biopsy
Age (yrs)32.6 ± 9.630.4 ± 11.40.26
Female (%)51.7%32.2%0.04
MAP (mmHg)93.30 ± 10.6493.83 ± 9.020.77
eGFR (ml/min per 1.73 m2)81.79 ± 24.5883.11 ± 30.760.80
Proteinuria (g/d)2.71 ± 2.593.55 ± 2.560.08
M1 (%)67.2%74.6%0.30
E25 (%)17.2%17.5%0.94
C1 (%)69.0%66.1%0.74
S1 (%)81%82.3%0.86
T0 (%)72.4%69.8%0.84
T1 (%)17.2%17.5%0.88
T2 (%)10.4%12.7%0.76
Follow-up
    Duration of follow-up (months)32 (12 to 74)38 (12 to 86)0.32
    TA-Up (g/d)0.5 ± 0.32.0 ± 1.1<0.001
    TA-MAP (mmHg)86.2 ± 7.091.6 ± 9.1<0.001
    ESRD (%)011.3%0.01
    eGFR slope (ml/min per 1.73 m2 per year)0.2 ± 0.7–0.2 ± 0.70.002
  • eGFR, estimated glomerular filtration rate; MAP, mean arterial pressure; TA-MAP, time-averaged MAP; TA-Up, time-averaged proteinuria; M1, mesangial hypercellularity score >0.5; E25, endocapillary hypercellularity involving more than 25% glomeruli; C1, crescent present; S1, segmental glomerulosclerosis present; T0, tubular atrophy/interstitial fibrosis range from 0 to 25%; T1, tubular atrophy/interstitial fibrosis range from 26 to 50%; T2, tubular atrophy/interstitial fibrosis >50%.